Author: Ravi Shankar

 PRESS RELEASE
Nantes, September 25th, 2026

H1 2026 Results: Continued cost discipline and balance sheet  restoration amidst a persistently challenging top-line environment 

Reminder: since July 2026, the Group has been operating with a strengthened balance sheet following the refinancing agreement reached with its main stakeholders. Full details are available in the press release dated July 31, 2026. 

Net sales reached €412.8m, down 7.1% vs LY (-5.8% LfL) in a subdued market

 €15m gross savings achieved

Working Capital improvement

• Net Sales reached €412.8m, down 7.1% YoY (-5.8% on a LfL basis):
  • Performance contracted further in Q2 (-9.8%) compared to Q1 (-4.5%), impacted by constrained inventory levels and a deliberate scale-back of promotional activities 
  • The store network keeps proving resilience at -3.0% LfL. Southern Europe remained almost flat (-1.0% LfL), while France declined by -4.0% LfL, in line with market trends (IPEA) while Online experienced a steeper decline (-11.8%)

• Profitability & Cost Savings:
  • Current EBIT stood at -€36.8m (vs. -€22.0m in H1 2025).
  • Gross Margin to 61.9% reflects promotional support in Q1 
  • €15m gross cost savings achieved partially offset lower volumes, driven by major efforts in logistics and transportation

• Cash Flow & Balance Sheet:
  • Free Cash Flow improved to -€49.8m (vs. -€64.9m in H1 2025), reflecting EBIT contraction offset by net working capital improvement driven by lower inventory 

François-Melchior de Polignac, CEO of Maisons du Monde, commented: “In the first half of 2026, we operated in a challenging market environment while managing constrained inventory levels. Faced with these headwinds, we remained intensely focused on our priorities: cost reduction, cash preservation, and maintaining customer satisfaction.

Following the refinancing completed in July, we now operate with a lighter and secured balance sheet. With the backing of our new majority shareholders, we have the financial stability and operational support required to execute our turnaround and build a profitable, sustainable model for the long term.” 

H1 2026 Sales

	H1 26	H1 25	%
€ in millions	Actual	Actual	Variation
Group GMV	483,3	513,1	(5,8%)
Net sales	412,8	444,6	(7,1%)
Like-for-like sales	404,0	428,9	(5,8%)
Sales by geography
France	223,4	239,3	(6,6%)
% of sales	54,1%	53,8%	0,3ppt
International	189,4	205,3	(7,8%)
% of sales	45,9%	46,2%	(0,3ppt)
Sales by distribution channel
Stores	302,4	319,4	(5,3%)
% of sales	73,2%	71,8%	1,4ppt
Online	110,4	125,2	(11,8%)
% of sales	26,8%	28,2%	(1,4ppt)
Sales by product category
Decoration	210,6	232,2	(9,3%)
% of sales	51,0%	52,2%	(1,2ppt)
Furniture	202,2	212,4	(4,8%)
% of sales	49,0%	47,8%	1,2ppt

Group sales for the first half of 2026 reached €412.8 million, down 7.1% overall and -5.8% at constant scope compared to H1 2025.

International sales declined at a faster pace, reflecting contrasted performances across regions, with resilient activity in Southern Europe offset by stronger pressure in Germany and Austria.

The Group continued the proactive management of its store network in line with its transformation plan. As of June 30, 2026, the store network stood at 326 stores, including 22 affiliates.

H1 2026 financial performance 

EBIT

	H1 26	H1 25	%
€ in millions	Actual	Actual	Variation
Net sales	412,8	444,6	(7,1%)
Cost of Goods Sold (1)	(157,2)	(158,5)	(0,8%)
Gross Margin	255,5	286,1	(10,7%)
As a % of net Sales	61,9%	64,3%	(2,4ppt)
Stores and central costs	(159,3)	(159,3)	(0,0%)
Logistic costs	(69,1)	(80,8)	(14,5%)
Operating costs	(228,4)	(240,1)	(4,8%)
Current EBITDA	27,1	46,0	(41,0%)
As a % of net Sales	6,6%	10,3%	(3,7ppt)
D&A	(64,0)	(68,0)	(5,9%)
As a % of net Sales	(15,5%)	(15,3%)	(0,2ppt)
Current EBIT	(36,8)	(22,0)	n.a
As a % of net Sales	(8,9%)	(4,9%)	(4,0ppt)

(1) The difference in amount with the cost of sales in the consolidated income statements corresponds to the net operating expenses of the factory and the container traction company.

Gross margin rate decreased by 240 basis points to 61.9% compared to H1 2025. This contraction was primarily driven by higher promotional activity in Q1 and a challenging comparison base due to a non-recurring favorable item in H1 2025. During Q2, we took the deliberate decision to reduce promotional intensity. 

Operating costs totaled €228 million, down 4.8% year-on-year. This reduction reflects the tangible benefits of the €15 million gross cost-saving plan (which also impacted the cost of goods sold). These gains were partially offset by temporary inflationary pressures, notably on fuel, and transformation costs linked to ongoing IT investments.

Current EBITDA stood at €27 million, down from €46 million in H1 2025.

D&A decreased slightly, reflecting gradual Capex diminution and was also driven by the closure of 2 stores during the half-year.

Current EBIT stood at -€37 million (vs. -€22 million in H1 2025), reflecting top-line pressure and gross margin compression. 

NET RESULT

€ in millions	H1 26	H1 25
Current EBIT	(36,8)	(22,0)
Financial results	(14,8)	(11,3)
Other operating income & expenses	(10,1)	(49,1)
Other income & expenses	(0,8)	(1,2)
Fair value financial instruments	(0,6)	(1,0)
Income tax	(0,9)	9,0
Net income	(64,0)	(75,6)

Net loss for the period stood at -€64.0 million, compared to -€75.6 million in H1 2025. Main drivers included:

• €10.1 million in other operating expenses, covering store closure costs and restructuring expenses.
• A net financial result of -€14.8 million, showing an increased charge compared to H1 2025 due to a higher cost of debt.
• An income tax expense close to nil.

FREE CASH FLOW

(in EUR million)		H1 2026	H1 2025
Current EBITDA		27.1	46.0
Change in working capital		7.7	(41.0)
Change in other operating items		(7.0)	(3.3)
Net cash generated by/ (used in) operating activities		27.8	1.7
Capital expenditures (Capex)		(23.2)	(9.4)
Change in debt on fixed assets		2.4	(0.7)
Proceeds from sale of non-current assets		–	1.3
Interest received		0.2	–
Decrease in lease debt		(50.6)	(51.3)
Lease interest paid		(6.4)	(6.5)
Free cash flow		(49.8)	(64.9)

Free Cash Flow stood at -€49.8 million for H1 2026, improving from -€64.9 million in H1 2025.

• Capital Expenditure (Capex) reached €23.2 million, which includes a €10 million cash deposit required to secure operations during ongoing refinancing processes. Excluding this deposit, core investments amounted to €13.2 million, primarily allocated to IT tools and store network improvements.
• Net working capital improved, driven by strong inventory control, reducing stock levels from €181.8 million as of December 31, 2025, to €160.5 million as of June 30, 2026.

NET FINANCIAL DEBT

(€ in millions)		30 June 2026 Pro forma (1)	30 June 2026	31 December 2025
Term loan		41.0	51.3	50.4
Revolving Credit Facilities (RCF)		25.0	199.5	195.8
Other debt		0.9	7.2	7.3
Gross debt		66.9	258.0	253.5
Finance leases		427.2	427.2	473.9
Cash & Cash equivalents		(42.4)	(42.4)	(96.1)
Net debt (IFRS 16)		451.7	642.8	631.3
Less : lease debt (IFRS 16)		(427.2)	(427.2)	(473.9)
Plus : lease debt (finance lease)		0.1	0.1	0.3
Net debt (without IFRS 16)		24.6	215.7	157.7

1. Unaudited, as if the refinancing had been completed at 30 June 2026

In July 2026, the Group successfully reached an agreement with its key stakeholders, including the French State, Banking partners, and Investors to execute a comprehensive debt refinancing. On a restated basis, this agreement significantly de-leverages the Group, bringing Net Financial Debt down to €24.6 million as of June 30, 2026, and restoring a healthy balance sheet structure. 

The guarantees related to the New Financing provided by the Consortium and the Participating Banks are currently being put in place. As a reminder, these guarantees consist of:

• A security and management trust (fiducie sûreté et gestion) or a pledge over the Group’s strategic assets (including 100% of the shares in Maisons du Monde France held by the Company and 100% of the shares in the Group’s main operating subsidiaries, all intellectual property rights of Maisons du Monde France (including the trademark), all merchandise inventory belonging to Maisons du Monde France, intercompany receivables held by the Company and Maisons du Monde France, and the bank accounts of the Company and Maisons du Monde France);
• A joint and several guarantee from the Company covering all obligations of Maisons du Monde France under the new financing.

In this transition context, the Group is not providing financial guidance.

OTHERS

The Company’s Board of Directors consists of seven members, including three independent directors (John Browett, Cécile Cloarec, and Laure Hauseux, the latter possessing specific financial and accounting expertise). The other directors, in addition to Alteri Investors and Eicos Investment Group, are François-Melchior de Polignac (Chief Executive Officer) and Stéphane Boussard (employee representative director). 

Regarding its corporate governance code, Maisons du Monde previously applied the AFEP-MEDEF Code. At its meeting on September 25, the Board of Directors decided that the Group will now adhere to the MiddleNext “Corporate Governance Code for Small and Mid-Caps”. The Board considers this code more suited to the company’s size and specific characteristics, notably given the presence of a reference shareholder now holding nearly 95% of the Company’s share capital as well as the reduction of the number of Board members.

The Board of Directors meeting on 25 September also decided that the Board of Directors would from now on perform the duties assigned to the audit committee, pursuant to Article L. 821-68 4° of the French Commercial Code. 

The statutory auditors expect to issue an unqualified limited review report on the Group’s condensed interim consolidated financial statements as of June 30, 2026, including an emphasis-of-matter paragraph regarding the uncertainty related to the Group’s ability to continue as a going concern.

Consolidated income statement

		H1 2026		H1 2025
(in EUR million)
Retail sales and commissions related to ordinary activities		412.8		444.6
Other revenue		10.3		12.2
Total revenue		423.2		456.8
Cost of sales		(152.4)		(152.7)
Personnel expenses		(100.4)		(105.2)
External expenses		(144.7)		(155.5)
Depreciation, amortisation and allowance for provisions		(63.9)		(68.0)
Fair value – derivative financial instruments		(0.6)		(1.0)
Other income/(expenses) from operations		0.6		1.3
Current operating profit		(38.2)		(24.3)
Other operating income and expenses		(10.1)		(49.1)
Operating profit / (loss)		(48.3)		(73.3)
Cost of net debt		(8.5)		(5.7)
Cost of lease debt		(6.3)		(6.6)
Finance income		1.3		3.1
Finance expenses		(1.3)		(2.1)
Financial profit / (loss)		(14.8)		(11.3)
Profit / (loss) before income tax		(63.1)		(84.6)
Income tax		(0.9)		9.0
Profit / (loss)		(64.0)		(75.6)
Attributable to:
·   Owners of the parent		(63.9)		(75.5)
·   Non-controlling interests		–		(0.1)
Reported EPS (in €)		(1.66)		(1.96)

Consolidated balance sheet

ASSETS
Other intangible assets		189.2		190.7
Property, plant and equipment		82.9		87.0
Right-of-use assets related to lease contracts		407.2		451.5
Other non-current financial assets		28.9		18.0
Deferred income tax assets		7.2		6.9
Derivative financial instruments		0.3		–
NON-CURRENT ASSETS		715.7		754.1
Inventory		160.5		181.8
Trade receivables and other current receivables		51.2		47.5
Current income tax assets		6.9		7.1
Derivative financial instruments		0.9		–
Cash and cash equivalents		42.4		96.1
CURRENT ASSETS		261.9		332.5
TOTAL ASSETS		977.6		1,086.6
EQUITY AND LIABILITIES
TOTAL EQUITY		23.0		78.1
Non-current borrowings		0.1		25.4
Medium and long-term lease liability		325.8		367.4
Deferred income tax liabilities		16.6		12.2
Post-employment benefits		8.7		9.1
Provisions		17.2		15.3
Derivative financial instruments		–		–
Other non-current liabilities		–
NON-CURRENT LIABILITIES		368.4		429.4
Current borrowings and convertible bonds		257.8		228.1
Short-term lease liability		101.4		106.5
Trade payables and other current payables		222.3		228.8
Provisions		3.6		5,3
Current income tax liabilities		1.1		0.6
Derivative financial instruments		–		9.8
Others current liabilities		–		–
CURRENT LIABILITIES		586.2		579.1
TOTAL LIABILITIES		954.6		1,008.5
TOTAL EQUITY AND LIABILITIES		977.6		1,086.6

Consolidated cash flow statement

(in EUR million – IFRS 16)		H1 2026		H1 2025
Net result		(64.0)		(75.6)
Adjustments for:
·   Depreciation, amortisation, and allowance for provisions		64.3		113.2
·   Net gain/(loss) on disposals		2.8		0.8
·   Fair value – derivative financial instruments		0.6		1.0
·   Change in fair value – unconsolidated investments		–		–
·   Share-based payments		(0.1)		0.1
·   Other		–		–
·   Cost of net financial debt		8.5		5.7
·   Cost of lease debt		6.3		6.6
·   Interest received		(0.2)		–
·   Income Tax		0.9		(9.0)
Change in operating working capital requirement		7.7		(41.0)
Income tax paid		0.9		(0.1)
Net cash generated by/(used in) operating activities(a)		27.8		1.7
Acquisition of non-current assets:
·   Property, plant and equipment		(8.1)		(4.7)
·   Intangible assets		(4.4)		(4.9)
Change in loans and advances granted		(10.8)		0.3
Disposal of financial assets
Change in debts on fixed assets		2.4		(0.7)
Sale of non-current assets		–		1.3
Interest received		0.2		–
Net cash generated by/(used in) investing activities(b)		(20.6)		(8.8)
Impact of changes in scope of consolidation without change of control
Proceeds from issuance of borrowings		0.4		104.2
Repayment of borrowings		(0.9)		(27.6)
Decrease of lease debt		(50.6)		(51.3)
Acquisitions (net) of treasury shares		(0.1)		(0.3)
Dividends paid
Interest paid		(4.0)		(4.5)
Interest on lease debt		(6.4)		(6.5)
Net cash generated by/(used in) financing activities(c)		(61.5)		14.0
Exchange gains/(losses) on cash and cash equivalents		0.3		(1.1)
Net increase/(decrease) in cash & cash equivalents(a)+(b)+(c)		(54.1)		5.8
Cash & cash equivalents at period begin		96.1		90.5
Cash & cash equivalents at period end		42.0		96.3

In addition to the financial indicators set out in International Financial Reporting Standards (IFRS), Maisons du Monde’s management uses several non-IFRS metrics to evaluate, monitor and manage its business. The non- IFRS operational and statistical information related to Group’s operations included in this press release is unaudited and has been taken from internal reporting systems. Although none of these metrics are measures of financial performance under IFRS, the Group believes that they provide important insight into the operations and strength of its business. These metrics may not be comparable to similar terms used by competitors or other companies.

Sales: it includes the revenue from sales of decorative items and furniture through i) Stores (owned or affiliates), ii) to franchisees, iii) websites and iv) B2B activities. They also include marketplace commissions.

Like-for-like sales (LFL) growth: Represents the percentage change in sales from the Group’s retail stores, websites and B2B activities, net of product returns between one financial period (n) and the comparable preceding financial period (n-1), excluding changes in sales attributable to stores that opened or were closed during either of the comparable periods. Sales attributable to stores that closed temporarily for refurbishment during any of the periods are included. 

Gross margin: Is defined as sales minus cost of sales. Gross margin is also expressed as a percentage of Sales. 

Current EBITDA: Is defined as current operating profit, excluding: 

1. i. depreciation, amortization, and allowance for provisions and, 
2. ii. the change in the fair value of derivative financial instruments. The EBITDA margin is calculated as EBITDA divided by Sales. 

LTM EBITDA: Last twelve months EBITDA before IFRS 16

Current EBIT: Is defined as current EBITDA minus depreciation, amortization, and allowance for provisions. The EBIT margin is calculated as EBIT divided by Sales. 

Net debt (without IFRS 16) : Is defined as the Group’s finance leases, unsecured term loan, unsecured revolving credit facilities, deposits and bank borrowings, net of cash and cash equivalents. 

Free cash flow: Is defined as net cash from operating activities less the sum of capital expenditures (capital outlays for property, plant and equipment, intangible, other non-current assets, change in debt on fixed assets, proceeds from disposal of non-current assets and financial) and reduction of rental debt and interest on rental debt.

Disclaimer: Forward Looking Statement

This press release contains certain statements that constitute “forward-looking statements,” including but not limited to statements that are predictions of or indicate future events, trends, plans or objectives, based on certain assumptions or which do not directly relate to historical or current facts. Such forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the future results expressed, forecasted or implied by such forward- looking statements. Accordingly, no representation is made that any of these statements or forecasts will come to pass or that any forecast results will be achieved. Any forward-looking statements included in this press release speak only as of the date hereof and will not give rise to updates or revision. For a more complete list and description of such risks and uncertainties, refer to Maisons du Monde’s filings with the French Autorité des marchés financiers.

Financial agenda

The below financial calendar is provided for indicative purposes only and may be subject to change, please refer to our Corporate Web Site

22 October 2026 Q3 and 9-month 2026 Sales

About Maisons du Monde

Maisons du Monde is the leading player in inspiring, accessible, and sustainable home and decoration. The Brand offers a rich and constantly refreshed range of furniture and decorative items in a multitude of styles. Leveraging a highly efficient omnichannel model and direct access to consumers, the Group generates over 50% of its sales through its online platform and operates in 8 European countries.

corporate.maisonsdumonde.com

Contacts

Investor Relations	Press Relations
Denis Lamoureux Tel: (+33) 6 46 35 09 95	Pierre Barbe Tel: (+33) 6 23 23 08 51
dlamoureux@maisonsdumonde.com	pbarbe@maisonsdumonde.com Michelle Kamar Tel : (+33) 6 09 24 42 42 michelle@source-rp.com

Attachment

• Press release – Maisons du Monde I H1 26 Financial results

Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its direct cytotoxic activity

HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin (naxtarubicin), in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity. The findings are being presented at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, held September 25–28, 2026 in San Diego, California.

In preclinical models of pancreatic cancer, Annamycin’s antitumor activity appears to depend in part on CD8+ T cells, the immune system’s primary tumor-killing cells. The finding suggests Annamycin may do more than kill cancer cells directly; it may also expose tumors that are typically considered immunologically “cold” to immune attack.

Pancreatic cancer is among the most treatment-resistant solid tumors, and its characteristically “cold” immune microenvironment is one reason checkpoint inhibitors have shown limited single-agent activity in the disease. Preclinical evidence that Annamycin’s activity is partly immune-mediated points to a potential basis for combination approaches, and complements the immune-modulating mechanism of the Company’s WP1066 program.

Title: “Turning cold pancreatic tumors hot: Antitumor activity of Annamycin is partially mediated by CD8+ T cell cytotoxicity”
Author/Presenter: Angela T. Alistar, MD, Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center
Congress: AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development
Dates: September 25–28, 2026
Location: Hilton San Diego Bayfront, San Diego, California

These findings were generated in preclinical models. Preclinical results may not be predictive of results in humans, and Annamycin is not currently in clinical development for the treatment of pancreatic cancer.

The abstract for this presentation was published today as a supplement to the September 15, 2026 issue of Cancer Research.

“Annamycin represents a fundamental re-engineering of the anthracycline, one designed to increase efficacy and avoid multidrug resistance and the cardiotoxicity of currently prescribed agents,” said Walter Klemp, Chairman, President and Chief Executive Officer of Moleculin. “These data point to an unexpected additional benefit. In preclinical models of pancreatic cancer, Annamycin’s antitumor activity appears to depend in part on the immune system. If that observation holds, it broadens both where Annamycin might be useful and how it might be combined.”

Annamycin’s lead clinical program remains the ongoing MIRACLE trial evaluating AnnAraC in patients with relapsed or refractory acute myeloid leukemia (AML), which is the Company’s primary development focus and the basis of its near-term milestones. The pancreatic cancer findings described above are preclinical and are not part of the MIRACLE trial.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 2/3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, the potential immune-mediated mechanism of action of Annamycin, the relevance of preclinical findings in pancreatic cancer to the treatment of human disease, and the potential for Annamycin to be combined with other agents. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

• SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model – 
• Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy –
• SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009 activity against MYC-driven pancreatic cancer biology –

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical data from studies evaluating SLS009 (tambiciclib), its highly selective cyclin-dependent kinases 9 (CDK9) inhibitor, in patient-derived organoid models of pancreatic ductal adenocarcinoma (PDAC). The data are being presented at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, being held September 25–28, 2026, in San Diego. The timing of this announcement reflects AACR’s embargo policy, under which the data presented at the conference were restricted from publication until 1:00 p.m. ET today.

The studies, conducted in collaboration with researchers at the University of Wisconsin–Madison, evaluated SLS009 in MYC-amplified PDAC models, including a model resistant to the recently approved RAS inhibitor daraxonrasib (RMC-6236), as well as in combination with the BET inhibitor ZEN3694. MYC amplification is a biologically recognized mechanism of RAS targeting resistance.

“These findings provide encouraging preclinical evidence that CDK9 inhibition may enhance the activity of RAS-directed therapy in pancreatic cancer, including in the setting of MYC-associated resistance,” said Dragan Cicic, MD, Senior Vice President, Clinical Development of SELLAS. “In a daraxonrasib-resistant patient-derived model, SLS009 demonstrated substantially greater activity than daraxonrasib alone and further increased apoptosis and necrosis when the two agents were combined. Together with the synergistic activity observed with BET inhibition, these data support a broader strategy of using SLS009 to disrupt transcriptional programs that may contribute to resistance to RAS-targeted therapies and provide a strong rationale for further evaluation in pancreatic cancer patients.”

In a MYC-amplified, daraxonrasib-resistant patient-derived PDAC organoid model, SLS009 at 200 nM, daraxonrasib at 100 nM, and the combination of both agents were evaluated. Daraxonrasib was administered continuously, while SLS009 was removed after 24 hours to approximate its in vivo pharmacokinetic profile, with apoptosis and necrosis assessed at 72 hours.

A separate MYC-amplified patient-derived PDAC organoid model evaluated SLS009 in combination with the BET inhibitor ZEN3694. The combination demonstrated synergistic activity, including increased cancer cell death and sustained suppression of MYC transcription. Notably, these effects were observed at a ZEN3694 concentration substantially below reported physiologically achievable exposure levels.

Key findings:

• SLS009 demonstrated substantially greater single-agent activity than daraxonrasib in the daraxonrasib-resistant model, inducing 17.9% apoptosis versus 2.8% with daraxonrasib and 14.5% necrosis versus 2.7%.
• The combination of SLS009 and daraxonrasib further increased cancer cell death, inducing 36.5% apoptosis and 30.6% necrosis, compared with 17.9% and 14.5%, respectively, with SLS009 alone and 2.8% and 2.7%, respectively, with daraxonrasib monotherapy.
• SLS009 combined with ZEN3694 demonstrated synergistic activity, producing greater apoptosis and necrosis than either agent alone.
• The SLS009/ZEN3694 combination produced sustained suppression of MYC RNA and reduced expression of MYC and MCL-1 proteins, consistent with disruption of transcriptional pathways supporting tumor cell survival.

Together, the findings support further investigation of CDK9 inhibition as a strategy to enhance RAS-directed therapy and potentially address MYC-associated resistance in pancreatic cancer. The BET combination data provide additional mechanistic support for SLS009-based approaches designed to disrupt MYC-dependent transcriptional programs and suggest the potential to enhance BET inhibition at lower drug exposures.

“MYC is a particularly challenging oncogenic driver because it has historically been difficult to target directly,” said Jeremy D. Kratz, MD, Assistant Professor of Medicine and Principal Investigator at the University of Wisconsin–Madison. “Across these studies, CDK9 inhibition produced substantial activity in MYC-amplified pancreatic cancer models through two distinct therapeutic strategies. The activity of SLS009 supports its activity in a model with de novo daraxonrasib-resistance and together with the synergistic transcriptional suppression observed with BET inhibition, provides a strong rationale for further investigation of SLS009-based combinations in molecularly defined subsets of pancreatic cancer.”

Poster presentation details:

Title: Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids
Authors: Sawyer AG, Flannagan LE, Esguerra PN, Hossan MS, Kratz JD
Poster Number: A036 – September 27, 2026: 5-7pm PST

Title: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma
Authors: Esguerra PN, Cadarso M, Livingwell S, Hossan MD, Wong O, Kratz JD
Poster Number: B127 – September 27, 2026: 5-7pm PST

Title: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma
Authors: Cadarso M, Esguerra P, Flannagan L, Hossan MS, Kratz JD
Poster Number: B043 – September 27, 2026: 5-7pm PST

The posters will be available on SELLAS’ website following the conference.

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) – potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 19, 2026 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact

John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact

Joan Bosisio
VP, Scientific & Medical Communications
Simpson Healthcare
jbosisio@simpsonhealthcare.com

FAIRFAX, Va., Sept. 25, 2026 (GLOBE NEWSWIRE) — WidePoint Corporation (NYSE American: WYY), a leading provider of Secure Mobile Management and Managed Services Solutions, today provided an update regarding the Government Accountability Office (GAO) decision concerning the Department of Homeland Security (DHS) Cellular Wireless Managed Services (CWMS) 3.0 contract. The GAO has notified WidePoint that it has sustained the protest filed by TurningPoint Global Solutions regarding the award. It is important to note that a “sustained” protest does not necessarily conclude the procurement process; rather, it is a routine mechanism within federal contracting that may lead to various outcomes, including corrective actions or re-evaluations, as determined by the agency.

In accordance with standard federal procurement procedures and the protective order currently in place, the specific findings and recommendations of the GAO decision remain under seal and are not publicly available at this time. The attorneys for the parties are in the process of reviewing the protected decision for potential redactions of sensitive information before a public version of the decision is issued. As a result, the full details of the decision are not yet available to WidePoint or the public.

WidePoint is committed to a transparent and thorough process. Once the public decision is issued, the company will work with legal counsel to review the GAO decision and WidePoint’s options in response to it, and WidePoint is engaging with DHS to understand the agency’s next steps in response to the decision.

WidePoint continues to maintain a strong, productive relationship with DHS and remains fully focused on delivering exceptional service and value to all of our federal and commercial clients. Further updates will be provided as appropriate and in accordance with regulatory requirements.

About WidePoint
WidePoint Corporation (NYSE American: WYY) is a leading technology Managed Solution Provider (MSP) dedicated to securing and protecting the mobile workforce and enterprise landscape. WidePoint is recognized for pioneering technology solutions that include Identity & Access Management (IAM), Mobility Managed Services (MMS), Telecom Management, Information Technology as a Service, Cloud Security, and Analytics & Billing as a Service (ABaaS). To learn more, visit https://www.widepoint.com. 

WidePoint Investor Relations:
Gateway Group, Inc.
Matt Glover or John Yi
949-574-3860
WYY@gateway-grp.com

Orion Corporation: Acquisition of own shares during week 39, 2026

The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052.

Orion Corporation’s shares have been acquired as follows:

Date	Exchange transaction		Share trading code	Number of shares		Average price/ share (EUR)*	Total transaction value (EUR)
September 21, 2026	Buy	ORNBV		23,704	82.2724			1,950,184.97
September 22, 2026	Buy	ORNBV		22,639	83.2528			1,884,760.14
September 23, 2026	Buy	ORNBV		23,552	83.3016			1,961,919.28
September 24, 2026	Buy	ORNBV		23,842	82.5790			1,968,848.52
September 25, 2026	Buy	ORNBV		20,000	83.0657			1,661,314.00
Total during week 39/2026	Buy	ORNBV		113,737	82.8844			9,427,023.00

*Average price rounded to four decimal places

After these acquisitions, Orion Corporation holds a total of 730,383 treasury shares which all are Class B shares.

On behalf of Orion Corporation

Danske Bank A/S, Finland Branch
Antti Väliaho, Jonathan Nyberg

For more information, please contact:

Tuukka Hirvonen, Head of Investor Relations
Orion Corporation
Tel. +358 10 426 2721, tuukka.hirvonen@orionpharma.com

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.

Attachment

• FI0009014377_20260925

Rexel to acquire GCG,
a leading specialty infrastructure platform in the US,
a key milestone on Rexel’s strategic roadmap

Seizing a major opportunity to expand our US business, adding a c.$1.1bn sales specialty infrastructure platform Leveraging GCG’s exposure to high growth segments & strong value-added customer service $1.4bn Enterprise Value acquisition at an attractive <8x 2026e EBITDAaL multiple post run-rate synergies Reaching all strict financial criteria, including EPS accretion in year 1 & value creation by year 3, supported by targeted cost synergies Providing an accelerated path to Rexel’s mid-term financial objectives Financed through a mix of existing cash on hand and debt, alongside an equity raise of up to €500m to preserve credit rating and balance-sheet flexibility. Remain committed to an indebtedness ratio of c.2x from 2027 onwards

Rexel has entered into an agreement with Audax Private Equity (“Audax”) to acquire GCG, a leading US provider of specialty wire and cable, connectivity, power and engineered solutions for critical infrastructure applications. Headquartered in Chicago, Illinois, GCG operates 16 locations with approximately 950 employees and is expected to reach over $1.1 billion of revenue in 2026.

Compelling value-added service, exposed to high growth segments

GCG combines specialty distribution with a complete range of advanced services including engineering, custom assembly, product modification, kitting, testing and rapid fulfillment. A significant portion of its revenue is generated from proprietary offerings, while more than 75% incorporates value-added products or services. These capabilities allow GCG to participate further upstream in product design and specification, help customers reduce installation time and labor, and build more embedded customer relationships.

The acquisition will position Rexel at the center of several powerful mega trends reshaping the global economy and its electrification. More than 60% of GCG’s revenue is exposed to high growth segments including data centers, power/utilities infrastructure, grid modernization, communications, defense, utilities and other long-term growth markets where artificial intelligence, rising electricity demand and increasing technical complexity are driving sustained infrastructure investments.

Since 2019, GCG has delivered double-digit annual revenue growth and is expected to reach a c.11% EBITA margin in 2026, reflecting GCG’s exposure to structurally attractive end-markets, proprietary products, technical expertise and its value-add operating model.

Rexel’s Board of Directors has unanimously approved the acquisition of GCG.

Executing our value creating M&A strategy

This acquisition is fully aligned with Rexel’s strategy to accelerate further in its core geographies and is a strong driver of the Group’s accelerated sales growth.

Rexel also expects to generate meaningful cost synergies from GCG through scale, logistics optimization, insourcing and select efficiencies. In addition, the combination also creates significant commercial opportunities by bringing GCG’s engineered solutions and specialty distribution capabilities to Rexel’s broader customer base.                

The transaction values GCG at an Enterprise Value of approximately $1.4 billion, corresponding to a <8x 2026e EBITDAaL multiple including anticipated run-rate synergies. This transaction respects all financial M&A criteria, including EPS accretion in year 1 and value creation by year 3.

Preserving our balance sheet

Rexel plans to finance GCG through a mix of existing cash on hand, and debt for c.€800 million.

The Group also intends to raise up to €500 million equity through an accelerated bookbuilding offering (subject to market conditions), to preserve its credit rating and maintain a net financial debt / EBITDAaL ratio around 2x from 2027 onwards.

As such, Rexel will maintain a balanced capital allocation strategy between a consistent dividend policy of at least 40% payout and a self-funded value creative acquisition strategy allowing the Group to continue delivering solid growth and returns to shareholders.

The transaction is expected to close by 2026 year-end, subject to customary regulatory approvals and closing conditions.

Guillaume Texier, Chief Executive Officer of Rexel, commented: “The acquisition of GCG is an exciting and major step forward in Rexel’s strategy. It significantly expands our addressable market, strengthening our position in key, fast-growing segments. It moves Rexel into higher-value parts of the infrastructure value chain and creates a more complete offering across electrical power and digital connectivity. It is financially attractive, immediately accretive to adjusted earnings and to Rexel’s EBITA margin, with substantial additional value creation potential from synergies and commercial expansion. GCG also brings high-quality, talented teams with a strong reputation with customers, suppliers and partners, which will be key assets as we build a leading specialty infrastructure platform together. The acquisition of GCG, an exceptional platform combining strong growth, an attractive margin profile and differentiated capabilities is fully in line with Rexel’s Axelerate 28 strategy, which aims at shaping our portfolio towards more growth and more value-added, and is a significant step in the direction of achieving our mid-term objectives.”

Advisors

Guggenheim Securities and Rothschild & Co served as financial advisors to Rexel and Sidley Austin LLP served as legal advisor. Solomon Partners and J.P. Morgan served as financial advisors to GCG, with Kirkland & Ellis and Fredrikson & Byron serving as legal counsel.

Analyst call and further information

Rexel will be hosting a call for analysts and investors at 6.15pm CET on September 25^th, 2026. Participants are advised to join the call at least 10 minutes prior to the commencement of the call to register. Presentation materials will be available ahead of the call on the Rexel website. Please connect to the call via the following link: https://streamstudio.world-television.com/1524-2871-43792/en To dial in from France: +33 (0)1 70 91 87 04 (code: 596076) or from outside of France: +44 (0) 12 1281 8004 or +1 718 705 8796 (code: 596076)

About Rexel group        

Rexel, worldwide expert in the multichannel professional distribution of products and services for the energy world, addresses three main markets: residential, non-residential, and industrial. The Group supports its residential, non-residential, and industrial customers by providing a tailored and scalable range of products and services in energy management for construction, renovation, production, and maintenance. Rexel operates through a network of 1,876 branches in 17 countries, with 26,306 employees. The Group’s sales were €19.4 billion in 2025.

Rexel is listed on the Eurolist market of Euronext Paris (compartment A, ticker RXL, ISIN code FR0010451203). It is included in the following indices: MSCI World, CAC Next 20, SBF 120, CAC Large 60, CAC SBT 1.5 NR, CAC AllTrade, CAC AllShares, FTSE EuroMid, and STOXX600. Rexel is also part of the following SRI indices: FTSE4Good, Dow Jones Sustainability Index Europe, Euronext Sustainable Europe 120 and S&P Global Sustainability Yearbook 2025, in recognition of its performance in terms of Corporate Social Responsibility (CSR).

For more information, visit www.rexel.com/en.

About GCG

GCG is a leading value-added provider of wire, cable, connectivity, and automation solutions serving diverse markets. With a comprehensive offering of premier brands and custom solutions, GCG is the preferred provider for original equipment manufacturers, contractors, installers, and other end users in attractive, mission critical markets. GCG generates over $1 billion in annual revenue via more than 16 facilities. GCG has cable assembly operations and product engineering capabilities to support unique customer needs and is proud to be a leading wire and cable provider to the U.S. Navy.

About Audax Private Equity

Headquartered in Boston, with offices in San Francisco, New York, London and Hong Kong, Audax Private Equity is a leading private equity platform focused on investing across the North American middle market. Our objective is to accelerate value creation through our Buy & Build strategy and the Audax Value Agenda™, a holistic framework that seeks to enable, create, and protect value across every stage of the investment lifecycle. As of July 2026, Audax Private Equity had approximately $20.1 billion of assets under management and, since inception in 1999, has invested in more than 180 platforms and more than 1,500 add-on acquisitions. For more information, visit www.audaxprivateequity.com or follow us on LinkedIn.

Contacts

Financial analysts/investors

Ludovic Debailleux

+33 1 42 85 76 12

ludovic.debailleux@rexel.com

Press

Taddeo : Pierre-Jean Le Mauff

+33 7 77 78 58 67

Pierre-jean.lemauff@taddeo.fr

Disclaimer

The Group is exposed to fluctuations in copper prices in connection with its distribution of cable products. Cables accounted for approximately 16% of the Group’s sales and copper accounts for approximately 60% of the composition of cables. This exposure is indirect since cable prices also reflect copper suppliers’ commercial policies and the competitive environment in the Group’s markets. Changes in copper prices have an estimated so-called “recurring” effect and an estimated so called “non-recurring” effect on the Group’s performance assessed as part of the monthly internal reporting process of the Rexel Group: i) the recurring effect related to the change in copper-based cable prices corresponds to the change in value of the copper part included in the sales price of cables from one period to another. This effect mainly relates to the Group’s sales; ii) the non-recurring effect related to the change in copper-based cable prices corresponds to the effect of copper price variations on the sales price of cables between the time they are purchased and the time they are sold, until all such inventory has been sold (direct effect on gross profit). Practically, the non-recurring effect on gross profit is determined by comparing the historical purchase price for copper-based cable and the supplier price effective at the date of the sale of the cables by the Rexel Group. Additionally, the non-recurring effect on current EBITA corresponds to the non-recurring effect on gross profit, which may be offset, when appropriate, by the non-recurring portion of changes in the distribution and administrative expenses.

The impact of these two effects is assessed for as much of the Group’s total cable sales as possible, over each period. Group procedures require that entities that do not have the information systems capable of such exhaustive calculations to estimate these effects based on a sample representing at least 70% of the sales in the period. The results are then extrapolated to all cables sold during the period for that entity. Considering the sales covered, the Rexel Group considers such estimates of the impact of the two effects to be reasonable.

This press release does not constitute or form any part of an offer to sell, exchange or purchase, or solicitation of an offer to buy or exchange, any securities in the United States, Australia, Canada or Japan or in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The distribution of this press release may, in certain states or jurisdictions, be restricted by local legislations. Persons into whose possession this press release comes are required to inform themselves about and to observe any such potential local restrictions. This announcement is not for publication or distribution, directly or indirectly, in or into the United States, Australia, Canada or Japan.

Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offering of securities in the United States.

This document may contain statements of future expectations and other forward-looking statements. By their nature, they are subject to numerous risks and uncertainties, including those described in the Universal Registration Document registered with the French Autorité des Marchés Financiers (AMF) on March 10, 2026 under number D.26-0073. These forward-looking statements are not guarantees of Rexel’s future performance, Rexel’s actual results of operations, financial condition and liquidity as well as development of the industry in which Rexel operates may differ materially from those made in or suggested by the forward-looking statements contained in this release. The forward-looking statements contained in this communication speak only as of the date of this communication and Rexel does not undertake, unless required by law or regulation, to update any of the forward-looking statements after this date to conform such statements to actual results to reflect the occurrence of anticipated results or otherwise.

The market and industry data and forecasts included in this document were obtained from internal surveys, estimates, experts and studies, where appropriate, as well as external market research, publicly available information and industry publications. Rexel, its affiliates, directors, officers, advisors and employees have not independently verified the accuracy of any such market and industry data and forecasts and make no representations or warranties in relation thereto. Such data and forecasts are included herein for information purposes only.

This document includes only summary information and must be read in conjunction with Rexel’s Universal Registration Document registered with the AMF on March 10, 2026 under number D.26-0073, and the half-year financial report for the six month period ended June 30, 2026 which can be obtained from Rexel’s website (www.rexel.com) .

Attachment

• PR – 2026 09 Rexel to acquire GCG

MINNEAPOLIS, Sept. 25, 2026 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (the “Company,” “we,” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced that it will implement a 1-for-10 reverse stock split of its issued and outstanding shares of common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern Time on September 29, 2026. The Reverse Stock Split was approved by the Company’s stockholders at its Annual Meeting of Stockholders held on September 18, 2026, with the final ratio, within the range approved by stockholders, subsequently determined by the Company’s board of directors. The Reverse Stock Split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, and to broaden investor interest.

The Company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on September 29, 2026 under the Company’s existing trading symbol “ONMD” with the new CUSIP number 68270C 202.

At the effective time of the Reverse Stock Split, every ten (10) shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock without any change in the par value per share. The Reverse Split will reduce the number of shares of outstanding common stock from approximately 59,286,450 shares, the number of shares outstanding as of September 24, 2026, to approximately 5,928,645 shares of common stock. The total authorized number of shares will not be reduced. The Reverse Stock Split will also proportionately adjust the number of shares available under the Company’s equity incentive plans and the exercise price and number of shares underlying outstanding restricted stock units, warrants, and other equity instruments, in each case in accordance with their terms.

No fractional shares will be issued in connection with the Reverse Stock Split. Any fractional shares of common stock resulting from the Reverse Stock Split will be rounded up to the nearest whole share. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s relative interest in the Company’s equity securities, except for any adjustments for fractional shares.

Continental Stock Transfer & Trust Company is acting as the exchange agent and transfer agent for the Reverse Stock Split. Stockholders holding their shares electronically are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker or other nominee will have their positions adjusted to reflect the Reverse Stock Split, subject to such broker’s particular processes.

About OneMedNet Corporation

OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform is powered by Palantir Foundry and supports applications ranging from drug development and regulatory submissions to foundational AI model training.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements may describe our future plans and expectations and are based on the current beliefs, expectations and assumptions of the Company. These statements generally use terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or similar terms. Examples of forward-looking statements in this press release include but are not limited to statements about the timing and implementation of the Reverse Stock Split and the commencement of trading of the Company’s post-split common stock, the impact of the Reverse Stock Split on the Company’s securityholders, the potential for the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market and the expected number of shares of common stock to be issued and outstanding following the Reverse Stock Split.

We urge you to consider those factors, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “SEC”), any subsequently filed quarterly reports on Form 10-Q as well as in other documents that may have been subsequently filed by the Company, from time to time, with the SEC, in evaluating our forward-looking statements. In addition, any forward-looking statements represent the Company’ views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company does not assume any obligation to update any forward-looking statements unless required by law.

OneMedNet Contacts:

Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION

Marimekko Corporation, Stock Exchange Release, 25 September 2026 at 6.45 p.m. EEST

Marimekko Corporation: Repurchase of own shares during week 39/2026

Marimekko Corporation has acquired its own shares during week 39 in the Helsinki Stock Exchange as follows:

Trade date	Shares	Average price / share	Total cost
21.9.2026	12,700	9.5713	121,555.51
22.9.2026	12,442	9.6475	120,034.20
23.9.2026	11,788	9.6018	113,186.02
24.9.2026	12,296	9.5415	117,322.28
25.9.2026	13,800	9.5130	131,279.40
Total amount, week 39	63,026	9.5735	603,377.41

Marimekko Corporation now holds a total of 196,486 shares including the shares repurchased on 25 September 2026.       

On 14 September 2026, Marimekko announced that it will start acquiring the company’s own shares based on the authorization granted by the Annual General Meeting held on 16 April 2026. The repurchase of own shares is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052.

Details of the transactions are included as an appendix of this announcement.

On behalf of Marimekko Corporation
EVLI OYJ
Aleksi Jalava

Further information:
Anna Tuominen
tel. +358 40 584 6944
anna.tuominen@marimekko.com

DISTRIBUTION:
Nasdaq Helsinki Ltd
Key media

Attachment

• MEKKO_Trades_Week_39.xlsx

Press release  –  Regulated information

Brussels, September 25, 2026, 17:45 CEST

In line with Belgian transparency legislation (Law of May 2, 2007), Citigroup Inc. recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%.

Here is a summary of the notification:

Date on which the threshold is crossed	Voting rights after the transaction	Equivalent financial instruments after the transaction	Total
September 21, 2026	–	–	–

The notification, dated September 22, 2026, contains the following information:

• Reason for the notification:
  • Acquisition or disposal of voting securities or voting rights
  • Downward crossing of the lowest threshold
• Notified by: A parent undertaking or a controlling person
• Date on which the threshold is crossed: September 21, 2026
• Threshold of direct voting rights crossed: 3% downwards
• Denominator: 105,876,416
• Persons subject to the notification requirement: Citigroup Inc., 1209 North Orange Street in Wilmington, Delaware 19801, USA

Transparency notifications and the full chain of controlled undertakings through which the holding is effectively held are available on the Investor Relations Section of Solvay’s website.

Contacts

Investor relations

Geoffroy d’Oultremont: +32 478 88 32 96
Vincent Toussaint: +33 6 74 87 85 65
Charlotte Vandevenne: +32 471 68 01 66
investor.relations@solvay.com

Media relations

Peter Boelaert: +32 479 30 91 59
Laetitia Van Minnenbruggen: +32 484 65 30 47
media.relations@solvay.com

About Solvay 

Solvay, a pioneering chemical company with a legacy rooted in founder Ernest Solvay’s pivotal innovations in the soda ash process, is dedicated to delivering essential solutions globally through its workforce of around 8,400 employees. Since 1863, Solvay harnesses the power of chemistry to create innovative, sustainable solutions that answer the world’s most essential needs such as purifying the air we breathe and the water we drink, preserving our food supplies, protecting our health and well-being, creating eco-friendly clothing, making the tires of our cars more sustainable and cleaning and protecting our homes. Solvay’s unwavering commitment drives the transition to a carbon-neutral future by 2050, underscoring its dedication to sustainability and a fair and just transition. As a world-leading company with €4.3 billion in net sales in 2025, Solvay is listed on Euronext Brussels and Paris (SOLB). For more information about Solvay, please visit solvay.com or follow Solvay on Linkedin.

Ce communiqué de presse est également disponible en français.
Dit persbericht is ook in het Nederlands beschikbaar.

Attachments

• 20260922 – Notification Citi
• Press release

Ad hoc announcement pursuant to Art. 53 LR

U.S. clinical hold remains in place; study continues in all other countries

Company initiates expansion of clinical sites and enrollment in Europe, Asia and Latin America

Topline data from ENIGMA-TRS 1 expected in Q1 2027

MILAN and MORRISTOWN, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) — Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it has been informed by the U.S. Food and Drug Administration (FDA) that the hold on the enrollment of new patients will remain in place at U.S. sites in the Phase 3 ENIGMA-TRS 2 study with evenamide. Enrollment in the study continues outside the U.S. Newron anticipates receiving a written communication from the FDA with additional information regarding its decision and any further potential protocol changes that may be required to lift the hold.

Evenamide targets the modulation of excessive release of glutamate in patients suffering from treatment-resistant schizophrenia (TRS).

Newron is initiating the expansion of clinical sites and enrollment for ENIGMA-TRS 2 in Europe, Asia and Latin America. To date, approximately 80 patients have entered screening. The study is expected to enroll at least 400 patients following successful completion of the 42-day screening period.

The ENIGMA-TRS 1 study is currently ongoing in 20 countries, with ENIGMA-TRS 2 ongoing in four countries.

“Newron is highly confident in the significant body of clinical and preclinical safety data for evenamide, and we will continue to work constructively with the FDA to address the clinical hold,” said Ravi Anand, Chief Medical Officer of Newron.

About ENIGMA-TRS

ENIGMA-TRS 1 is an ongoing, international, 52-week, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation antipsychotics, including clozapine, will meet Treatment Response and Resistance Psychosis international consensus criteria for TRS. The study is expected to have enrolled at least 600 patients in the study by mid-October 2026, at study centers in 20 countries in Europe, Asia, Latin America, and Canada.

The primary assessment of efficacy and safety of ENIGMA-TRS 1 will be performed 12 weeks after randomization to treatment. Following this initial period, the study will continue to be double-blind and placebo-controlled until the 26- and 52-week time points. The primary efficacy endpoint of the trial will be the change from baseline in the Positive and Negative Syndrome Scale (PANSS) scores at 12 weeks. Newron expects to announce results from the 12-week primary endpoint assessment in Q1 2027.

ENIGMA-TRS 2 is taking place at centers in the U.S. and selected additional countries with the same screening procedure as the ENIGMA-TRS 1 trial. ENIGMA-TRS 2 will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase 3 study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide compared to placebo. In December 2025, ENIGMA-TRS 2 was initiated in the U.S., following approvals from the U.S, Food and Drug Administration (FDA) and the Institutional Review Board (IRB). The efficacy and safety analysis will be performed at the 12-week point following successful completion of the study. On April 29, 2026, Newron reported a hold by the FDA on the enrollment of new patients in the U.S. sites of the study, following Newron’s notification to the agency of the sudden unexpected death of a study participant at a clinical site outside the United States. The investigator assessed the event as unrelated to study treatment. Newron has informed the independent international safety monitoring board for the overall ENIGMA-TRS program, which has reviewed the event and recommended that the studies continue as designed. While U.S. patients entered screening, no U.S. patients have been dosed with evenamide, in the study.

About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase 3 development program. Clinical trial results to date demonstrate the benefits of this drug candidate in TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: https://www.newron.com and connect with us on LinkedIn.

For more information, please contact:

Newron
Stefan Weber – CEO; +39 02 6103 46 26, pr@newron.com

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com   

Switzerland
Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu

USA
John Fraunces, LifeSci Advisors; +1 917 355 2395, jfraunces@lifesciadvisors.com

Important Notices
This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.